_id
6919f1103c536f8df23185ce
Ticker
22UA.XETRA
Name
BioNTech SE
Exchange
XETRA
Address
An der Goldgrube 12, Mainz, Germany, 55131
Country
Germany
Sector
Healthcare
Industry
Biotechnology
Currency
EUR
Website
https://www.biontech.de
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Last Close
80.55
Volume
21827
Current Price
82.8
Change
0.9931719428926098
Last Updated
2025-12-30T11:49:51.201Z
Image
https://logo.clearbit.com/www.biontech.de
Ipo Date
-
Market Cap
19368687616
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
1518900000
Cost Of Revenue
136500000
Gross Profit
1382400000
Operating Expenses
1565800000
Operating Income
-46900000
Interest Expense
6300000
Pretax Income
24700000
Net Income
-28700000
Eps
-0.11935682888451894
Dividends Per Share
-
Shares Outstanding
240455450
Income Tax Expense
-
EBITDA
-
Operating Margin
-3.0877608795839095
Total Other Income Expense Net
-628900000
Cash
10092900000
Short Term Investments
4434700000
Receivables
699700000
Inventories
225700000
Total Current Assets
15830700000
Property Plant Equipment
1240700000
Total Assets
21341100000
Payables
399800000
Short Term Debt
0
Long Term Debt
192000000
Total Liabilities
2863800000
Equity
18477300000
Bs_currency_symbol
EUR
Depreciation
218000000
Change In Working Capital
976200000
Cash From Operations
146500000
Capital Expenditures
686900000
Cash From Investing
257100000
Cash From Financing
-38600000
Net Change In Cash
331000000
Cf_currency_symbol
EUR
PE
-
PB
1.077522758195191
ROE
-0.15532572399647135
ROA
-0.13448229004128184
FCF
-540400000
Fcf Percent
-0.3557837909013102
Piotroski FScore
2
Health Score
36
Deep Value Investing Score
6
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
5.3
Garp Investing Score
4.5
Growth Investing Score
3
Momentum Investing Score
4
Net Net Investing Score
2
Quality Investing Score
3
Value Investing Score
5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
1518900000
Quarters > 0 > income Statement > cost Of Revenue
136500000
Quarters > 0 > income Statement > gross Profit
1382400000
Quarters > 0 > income Statement > operating Expenses
1565800000
Quarters > 0 > income Statement > operating Income
-46900000
Quarters > 0 > income Statement > interest Expense
6300000
Quarters > 0 > income Statement > pretax Income
24700000
Quarters > 0 > income Statement > net Income
-28700000
Quarters > 0 > income Statement > eps
-0.11935682888451894
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
240455450
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
-3.0877608795839095
Quarters > 0 > income Statement > total Other Income Expense Net
-628900000
Quarters > 0 > income Statement > currency_symbol
EUR
Quarters > 0 > balance Sheet > cash
10092900000
Quarters > 0 > balance Sheet > short Term Investments
4434700000
Quarters > 0 > balance Sheet > receivables
699700000
Quarters > 0 > balance Sheet > inventories
225700000
Quarters > 0 > balance Sheet > total Current Assets
15830700000
Quarters > 0 > balance Sheet > property Plant Equipment
1240700000
Quarters > 0 > balance Sheet > total Assets
21341100000
Quarters > 0 > balance Sheet > payables
399800000
Quarters > 0 > balance Sheet > short Term Debt
0
Quarters > 0 > balance Sheet > long Term Debt
192000000
Quarters > 0 > balance Sheet > total Liabilities
2863800000
Quarters > 0 > balance Sheet > equity
18477300000
Quarters > 0 > balance Sheet > currency_symbol
EUR
Quarters > 0 > cash Flow > net Income
-823400000
Quarters > 0 > cash Flow > depreciation
218000000
Quarters > 0 > cash Flow > change In Working Capital
976200000
Quarters > 0 > cash Flow > cash From Operations
146500000
Quarters > 0 > cash Flow > capital Expenditures
686900000
Quarters > 0 > cash Flow > cash From Investing
257100000
Quarters > 0 > cash Flow > cash From Financing
-38600000
Quarters > 0 > cash Flow > net Change In Cash
331000000
Quarters > 0 > cash Flow > currency_symbol
EUR
Quarters > 0 > ratios > PE
-0.11935682888451894
Quarters > 0 > ratios > PB
1.077522758195191
Quarters > 0 > ratios > ROE
-0.15532572399647135
Quarters > 0 > ratios > ROA
-0.13448229004128184
Quarters > 0 > ratios > FCF
-540400000
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
-0.3557837909013102
Quarters > 0 > health Score
36
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
260800000
Quarters > 1 > income Statement > cost Of Revenue
49800000
Quarters > 1 > income Statement > gross Profit
211000000
Quarters > 1 > income Statement > operating Expenses
761900000
Quarters > 1 > income Statement > operating Income
-501100000
Quarters > 1 > income Statement > interest Expense
800000
Quarters > 1 > income Statement > pretax Income
-402700000
Quarters > 1 > income Statement > net Income
-386600000
Quarters > 1 > income Statement > eps
-1.6081616407940942
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
240398720
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
-192.13957055214723
Quarters > 1 > income Statement > total Other Income Expense Net
79100000
Quarters > 1 > income Statement > currency_symbol
EUR
Quarters > 1 > balance Sheet > cash
10269500000
Quarters > 1 > balance Sheet > short Term Investments
3767200000
Quarters > 1 > balance Sheet > receivables
1377000000
Quarters > 1 > balance Sheet > inventories
230700000
Quarters > 1 > balance Sheet > total Current Assets
15929100000
Quarters > 1 > balance Sheet > property Plant Equipment
1242100000
Quarters > 1 > balance Sheet > total Assets
21637600000
Quarters > 1 > balance Sheet > payables
504200000
Quarters > 1 > balance Sheet > short Term Debt
0
Quarters > 1 > balance Sheet > long Term Debt
217200000
Quarters > 1 > balance Sheet > total Liabilities
3132500000
Quarters > 1 > balance Sheet > equity
18505100000
Quarters > 1 > balance Sheet > currency_symbol
EUR
Quarters > 1 > cash Flow > net Income
-386600000
Quarters > 1 > cash Flow > depreciation
93800000
Quarters > 1 > cash Flow > change In Working Capital
264900000
Quarters > 1 > cash Flow > cash From Operations
-634200000
Quarters > 1 > cash Flow > capital Expenditures
648300000
Quarters > 1 > cash Flow > cash From Investing
1182400000
Quarters > 1 > cash Flow > cash From Financing
-27100000
Quarters > 1 > cash Flow > net Change In Cash
507600000
Quarters > 1 > cash Flow > currency_symbol
EUR
Quarters > 1 > ratios > PE
-1.6081616407940942
Quarters > 1 > ratios > PB
1.0756501729793406
Quarters > 1 > ratios > ROE
-2.0891538008440915
Quarters > 1 > ratios > ROA
-1.7867046252819165
Quarters > 1 > ratios > FCF
-1282500000
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-4.917561349693251
Quarters > 1 > health Score
34
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
182800000
Quarters > 2 > income Statement > cost Of Revenue
46100000
Quarters > 2 > income Statement > gross Profit
136700000
Quarters > 2 > income Statement > operating Expenses
716900000
Quarters > 2 > income Statement > operating Income
-534100000
Quarters > 2 > income Statement > interest Expense
12400000
Quarters > 2 > income Statement > pretax Income
-445400000
Quarters > 2 > income Statement > net Income
-415800000
Quarters > 2 > income Statement > eps
-1.7296704033593044
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
240392620
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
-292.17724288840265
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > income Statement > currency_symbol
EUR
Quarters > 2 > balance Sheet > cash
10184900000
Quarters > 2 > balance Sheet > short Term Investments
3924900000
Quarters > 2 > balance Sheet > receivables
966500000
Quarters > 2 > balance Sheet > inventories
254400000
Quarters > 2 > balance Sheet > total Current Assets
15625500000
Quarters > 2 > balance Sheet > property Plant Equipment
1268000000
Quarters > 2 > balance Sheet > total Assets
21182400000
Quarters > 2 > balance Sheet > payables
443800000
Quarters > 2 > balance Sheet > short Term Debt
0
Quarters > 2 > balance Sheet > long Term Debt
237500000
Quarters > 2 > balance Sheet > total Liabilities
2255800000
Quarters > 2 > balance Sheet > equity
18926600000
Quarters > 2 > balance Sheet > currency_symbol
EUR
Quarters > 2 > cash Flow > net Income
-415800000
Quarters > 2 > cash Flow > depreciation
42800000
Quarters > 2 > cash Flow > change In Working Capital
-316800000
Quarters > 2 > cash Flow > cash From Operations
-780700000
Quarters > 2 > cash Flow > capital Expenditures
618100000
Quarters > 2 > cash Flow > cash From Investing
1246800000
Quarters > 2 > cash Flow > cash From Financing
-13800000
Quarters > 2 > cash Flow > net Change In Cash
423000000
Quarters > 2 > cash Flow > currency_symbol
EUR
Quarters > 2 > ratios > PE
-1.7296704033593044
Quarters > 2 > ratios > PB
1.05166849492249
Quarters > 2 > ratios > ROE
-2.196908055329536
Quarters > 2 > ratios > ROA
-1.9629503738953094
Quarters > 2 > ratios > FCF
-1398800000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-7.652078774617068
Quarters > 2 > health Score
34
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
1190000000
Quarters > 3 > income Statement > cost Of Revenue
221000000
Quarters > 3 > income Statement > gross Profit
969000000
Quarters > 3 > income Statement > operating Expenses
322800000
Quarters > 3 > income Statement > operating Income
148600000
Quarters > 3 > income Statement > interest Expense
13500000
Quarters > 3 > income Statement > pretax Income
301200000
Quarters > 3 > income Statement > net Income
259500000
Quarters > 3 > income Statement > eps
1.0813815680907843
Quarters > 3 > income Statement > dividends Per Share
0
Quarters > 3 > income Statement > shares Outstanding
239970800
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
12.487394957983193
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > income Statement > currency_symbol
EUR
Quarters > 3 > balance Sheet > cash
9761900000
Quarters > 3 > balance Sheet > short Term Investments
7021700000
Quarters > 3 > balance Sheet > receivables
1473900000
Quarters > 3 > balance Sheet > inventories
283300000
Quarters > 3 > balance Sheet > total Current Assets
18803500000
Quarters > 3 > balance Sheet > property Plant Equipment
1183400000
Quarters > 3 > balance Sheet > total Assets
22529700000
Quarters > 3 > balance Sheet > payables
426700000
Quarters > 3 > balance Sheet > short Term Debt
0
Quarters > 3 > balance Sheet > long Term Debt
214700000
Quarters > 3 > balance Sheet > total Liabilities
3118600000
Quarters > 3 > balance Sheet > equity
19411100000
Quarters > 3 > balance Sheet > currency_symbol
EUR
Quarters > 3 > cash Flow > net Income
259500000
Quarters > 3 > cash Flow > depreciation
298000000
Quarters > 3 > cash Flow > change In Working Capital
1138300000
Quarters > 3 > cash Flow > cash From Operations
207700000
Quarters > 3 > cash Flow > capital Expenditures
452300000
Quarters > 3 > cash Flow > cash From Investing
-2081200000
Quarters > 3 > cash Flow > cash From Financing
-45900000
Quarters > 3 > cash Flow > net Change In Cash
-1901800000
Quarters > 3 > cash Flow > currency_symbol
EUR
Quarters > 3 > ratios > PE
1.0813815680907843
Quarters > 3 > ratios > PB
1.0236195908526564
Quarters > 3 > ratios > ROE
1.3368639592810299
Quarters > 3 > ratios > ROA
1.1518129402522004
Quarters > 3 > ratios > FCF
-244600000
Quarters > 3 > ratios > Piotroski FScore
3
Quarters > 3 > ratios > fcf Percent
-0.20554621848739496
Quarters > 3 > health Score
52
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
2751100000
Annuals > 0 > income Statement > cost Of Revenue
415500000
Annuals > 0 > income Statement > gross Profit
2335600000
Annuals > 0 > income Statement > operating Expenses
4065400000
Annuals > 0 > income Statement > operating Income
-1314300000
Annuals > 0 > income Statement > interest Expense
52500000
Annuals > 0 > income Statement > pretax Income
-677700000
Annuals > 0 > income Statement > net Income
-665300000
Annuals > 0 > income Statement > eps
-2.7724205982991164
Annuals > 0 > income Statement > dividends Per Share
0
Annuals > 0 > income Statement > shares Outstanding
239970804
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
-47.77361782559703
Annuals > 0 > income Statement > total Other Income Expense Net
-507000000
Annuals > 0 > income Statement > currency_symbol
EUR
Annuals > 0 > balance Sheet > cash
9761900000
Annuals > 0 > balance Sheet > short Term Investments
7021700000
Annuals > 0 > balance Sheet > receivables
1463900000
Annuals > 0 > balance Sheet > inventories
283300000
Annuals > 0 > balance Sheet > total Current Assets
18803500000
Annuals > 0 > balance Sheet > property Plant Equipment
1183400000
Annuals > 0 > balance Sheet > total Assets
22529700000
Annuals > 0 > balance Sheet > payables
426700000
Annuals > 0 > balance Sheet > short Term Debt
0
Annuals > 0 > balance Sheet > long Term Debt
214700000
Annuals > 0 > balance Sheet > total Liabilities
3118600000
Annuals > 0 > balance Sheet > equity
19411100000
Annuals > 0 > balance Sheet > currency_symbol
EUR
Annuals > 0 > cash Flow > net Income
-677700000
Annuals > 0 > cash Flow > depreciation
298000000
Annuals > 0 > cash Flow > change In Working Capital
1138300000
Annuals > 0 > cash Flow > cash From Operations
207700000
Annuals > 0 > cash Flow > capital Expenditures
452300000
Annuals > 0 > cash Flow > cash From Investing
-2081200000
Annuals > 0 > cash Flow > cash From Financing
-45900000
Annuals > 0 > cash Flow > net Change In Cash
-1901800000
Annuals > 0 > cash Flow > currency_symbol
EUR
Annuals > 0 > ratios > PE
-2.7724205982991164
Annuals > 0 > ratios > PB
1.000748879960435
Annuals > 0 > ratios > ROE
-3.427420393486201
Annuals > 0 > ratios > ROA
-2.952990940846971
Annuals > 0 > ratios > FCF
-244600000
Annuals > 0 > ratios > Piotroski FScore
2
Annuals > 0 > ratios > fcf Percent
-0.08890989058921886
Annuals > 0 > health Score
36
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
3819000000
Annuals > 1 > income Statement > cost Of Revenue
599800000
Annuals > 1 > income Statement > gross Profit
3219200000
Annuals > 1 > income Statement > operating Expenses
3128600000
Annuals > 1 > income Statement > operating Income
690400000
Annuals > 1 > income Statement > interest Expense
184400000
Annuals > 1 > income Statement > pretax Income
1186100000
Annuals > 1 > income Statement > net Income
930300000
Annuals > 1 > income Statement > eps
3.91333315259284
Annuals > 1 > income Statement > dividends Per Share
0
Annuals > 1 > income Statement > shares Outstanding
237725735
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
18.078030898140874
Annuals > 1 > income Statement > total Other Income Expense Net
-67800000
Annuals > 1 > income Statement > currency_symbol
EUR
Annuals > 1 > balance Sheet > cash
11663700000
Annuals > 1 > balance Sheet > short Term Investments
4885300000
Annuals > 1 > balance Sheet > receivables
2155700000
Annuals > 1 > balance Sheet > inventories
357700000
Annuals > 1 > balance Sheet > total Current Assets
19527300000
Annuals > 1 > balance Sheet > property Plant Equipment
971600000
Annuals > 1 > balance Sheet > total Assets
23006300000
Annuals > 1 > balance Sheet > payables
354000000
Annuals > 1 > balance Sheet > short Term Debt
0
Annuals > 1 > balance Sheet > long Term Debt
191000000
Annuals > 1 > balance Sheet > total Liabilities
2760400000
Annuals > 1 > balance Sheet > equity
20245900000
Annuals > 1 > balance Sheet > currency_symbol
EUR
Annuals > 1 > cash Flow > net Income
930300000
Annuals > 1 > cash Flow > depreciation
183400000
Annuals > 1 > cash Flow > change In Working Capital
4578500000
Annuals > 1 > cash Flow > cash From Operations
5371400000
Annuals > 1 > cash Flow > capital Expenditures
705500000
Annuals > 1 > cash Flow > cash From Investing
-6954500000
Annuals > 1 > cash Flow > cash From Financing
-778600000
Annuals > 1 > cash Flow > net Change In Cash
-2211400000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
3.91333315259284
Annuals > 1 > ratios > PB
0.9505084114931912
Annuals > 1 > ratios > ROE
4.595004420648132
Annuals > 1 > ratios > ROA
4.043674993371381
Annuals > 1 > ratios > FCF
4665900000
Annuals > 1 > ratios > Piotroski FScore
3
Annuals > 1 > ratios > fcf Percent
1.221759622937942
Annuals > 1 > health Score
75
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
17310600000
Annuals > 2 > income Statement > cost Of Revenue
2995000000
Annuals > 2 > income Statement > gross Profit
14315600000
Annuals > 2 > income Statement > operating Expenses
5009800000
Annuals > 2 > income Statement > operating Income
12642700000
Annuals > 2 > income Statement > interest Expense
341900000
Annuals > 2 > income Statement > pretax Income
12954100000
Annuals > 2 > income Statement > net Income
9434400000
Annuals > 2 > income Statement > eps
38.790343546416125
Annuals > 2 > income Statement > dividends Per Share
484300000
Annuals > 2 > income Statement > shares Outstanding
243215170
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
13093600000
Annuals > 2 > income Statement > operating Margin
73.03444132496851
Annuals > 2 > income Statement > total Other Income Expense Net
623700000
Annuals > 2 > income Statement > currency_symbol
EUR
Annuals > 2 > balance Sheet > cash
13875100000
Annuals > 2 > balance Sheet > short Term Investments
189400000
Annuals > 2 > balance Sheet > receivables
7145600000
Annuals > 2 > balance Sheet > inventories
439600000
Annuals > 2 > balance Sheet > total Current Assets
21922000000
Annuals > 2 > balance Sheet > property Plant Equipment
821100000
Annuals > 2 > balance Sheet > total Assets
23279100000
Annuals > 2 > balance Sheet > payables
204100000
Annuals > 2 > balance Sheet > short Term Debt
0
Annuals > 2 > balance Sheet > long Term Debt
2100000
Annuals > 2 > balance Sheet > total Liabilities
3223500000
Annuals > 2 > balance Sheet > equity
20055600000
Annuals > 2 > balance Sheet > currency_symbol
EUR
Annuals > 2 > cash Flow > net Income
9434400000
Annuals > 2 > cash Flow > depreciation
123300000
Annuals > 2 > cash Flow > change In Working Capital
252400000
Annuals > 2 > cash Flow > cash From Operations
13577400000
Annuals > 2 > cash Flow > capital Expenditures
363300000
Annuals > 2 > cash Flow > cash From Investing
-35300000
Annuals > 2 > cash Flow > cash From Financing
-1419300000
Annuals > 2 > cash Flow > net Change In Cash
12182400000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
38.790343546416125
Annuals > 2 > ratios > PB
0.9816843181704861
Annuals > 2 > ratios > ROE
47.041225393406336
Annuals > 2 > ratios > ROA
40.52733997448355
Annuals > 2 > ratios > FCF
13214100000
Annuals > 2 > ratios > Piotroski FScore
3
Annuals > 2 > ratios > fcf Percent
0.7633530900142109
Annuals > 2 > health Score
85
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
18976700000
Annuals > 3 > income Statement > cost Of Revenue
2911500000
Annuals > 3 > income Statement > gross Profit
16065200000
Annuals > 3 > income Statement > operating Expenses
4060800000
Annuals > 3 > income Statement > operating Income
15283800000
Annuals > 3 > income Statement > interest Expense
365700000
Annuals > 3 > income Statement > pretax Income
15046400000
Annuals > 3 > income Statement > net Income
10292500000
Annuals > 3 > income Statement > eps
42.439538038464136
Annuals > 3 > income Statement > dividends Per Share
0
Annuals > 3 > income Statement > shares Outstanding
242521490
Annuals > 3 > income Statement > income Tax Expense
4753900000
Annuals > 3 > income Statement > EBITDA
15127000000
Annuals > 3 > income Statement > operating Margin
80.53981988438453
Annuals > 3 > income Statement > total Other Income Expense Net
156300000
Annuals > 3 > income Statement > currency_symbol
EUR
Annuals > 3 > balance Sheet > cash
1692700000
Annuals > 3 > balance Sheet > short Term Investments
381600000
Annuals > 3 > balance Sheet > receivables
12381700000
Annuals > 3 > balance Sheet > inventories
502500000
Annuals > 3 > balance Sheet > total Current Assets
15072300000
Annuals > 3 > balance Sheet > property Plant Equipment
520400000
Annuals > 3 > balance Sheet > total Assets
15830800000
Annuals > 3 > balance Sheet > payables
160000000
Annuals > 3 > balance Sheet > short Term Debt
0
Annuals > 3 > balance Sheet > long Term Debt
17900000
Annuals > 3 > balance Sheet > total Liabilities
3937100000
Annuals > 3 > balance Sheet > equity
11893700000
Annuals > 3 > balance Sheet > currency_symbol
EUR
Annuals > 3 > cash Flow > net Income
10292500000
Annuals > 3 > cash Flow > depreciation
75200000
Annuals > 3 > cash Flow > change In Working Capital
-14199300000
Annuals > 3 > cash Flow > cash From Operations
889700000
Annuals > 3 > cash Flow > capital Expenditures
127500000
Annuals > 3 > cash Flow > cash From Investing
-566100000
Annuals > 3 > cash Flow > cash From Financing
94200000
Annuals > 3 > cash Flow > net Change In Cash
482500000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
42.439538038464136
Annuals > 3 > ratios > PB
1.6506313943936706
Annuals > 3 > ratios > ROE
86.5374105618941
Annuals > 3 > ratios > ROA
65.01566566440104
Annuals > 3 > ratios > FCF
762200000
Annuals > 3 > ratios > Piotroski FScore
4
Annuals > 3 > ratios > fcf Percent
0.04016504450194185
Annuals > 3 > health Score
71
Valuation > metrics > PE
-0.11935682888451894
Valuation > metrics > PB
1.077522758195191
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-0.15532572399647135
Profitability > metrics > ROA
-0.1812933098346883
Profitability > metrics > Net Margin
-0.01889525314372243
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.15499017713626992
Risk > metrics > Interest Coverage
-7.444444444444445
Risk > final Score
30
Risk > verdict
High
Liquidity > metrics > Current Ratio
39.59654827413707
Liquidity > metrics > Quick Ratio
39.032016008004
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
80
Prev Valuations > 2
100
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
37
Prev Risks > 0
-2445
Prev Risks > 1
-112
Prev Risks > 2
100
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T23:05:12.011Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-10
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-0.06
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-11-03
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
BeforeMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.1194
Earnings History > 1 > eps Estimate
0.1
Earnings History > 1 > eps Difference
-0.2194
Earnings History > 1 > surprise Percent
-219.4
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-08-04
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
BeforeMarket
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-1.6
Earnings History > 2 > eps Estimate
-1.41
Earnings History > 2 > eps Difference
-0.19
Earnings History > 2 > surprise Percent
-13.4752
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-05-05
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
BeforeMarket
Earnings History > 3 > currency
EUR
Earnings History > 3 > eps Actual
-1.73
Earnings History > 3 > eps Estimate
-2
Earnings History > 3 > eps Difference
0.27
Earnings History > 3 > surprise Percent
13.5
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2025-03-10
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
BeforeMarket
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
1.0814
Earnings History > 4 > eps Estimate
0.4767
Earnings History > 4 > eps Difference
0.6047
Earnings History > 4 > surprise Percent
126.8513
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-11-04
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
AfterMarket
Earnings History > 5 > currency
EUR
Earnings History > 5 > eps Actual
0.81
Earnings History > 5 > eps Estimate
-1.53
Earnings History > 5 > eps Difference
2.34
Earnings History > 5 > surprise Percent
152.9412
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-08-05
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
AfterMarket
Earnings History > 6 > currency
EUR
Earnings History > 6 > eps Actual
-3.398
Earnings History > 6 > eps Estimate
-2.02
Earnings History > 6 > eps Difference
-1.378
Earnings History > 6 > surprise Percent
-68.2178
Earnings History > 7 > period
2024-03-31
Earnings History > 7 > report Date
2024-05-06
Earnings History > 7 > date
2024-03-31
Earnings History > 7 > before After Market
AfterMarket
Earnings History > 7 > currency
EUR
Earnings History > 7 > eps Actual
-1.31
Earnings History > 7 > eps Estimate
0.699
Earnings History > 7 > eps Difference
-2.009
Earnings History > 7 > surprise Percent
-287.4106
Earnings History > 8 > period
2023-12-31
Earnings History > 8 > report Date
2024-03-20
Earnings History > 8 > date
2023-12-31
Earnings History > 8 > before After Market
AfterMarket
Earnings History > 8 > currency
EUR
Earnings History > 8 > eps Actual
1.8931
Earnings History > 8 > eps Estimate
3.22
Earnings History > 8 > eps Difference
-1.3269
Earnings History > 8 > surprise Percent
-41.2081
Earnings History > 9 > period
2023-09-30
Earnings History > 9 > report Date
2023-12-18
Earnings History > 9 > date
2023-09-30
Earnings History > 9 > before After Market
AfterMarket
Earnings History > 9 > currency
EUR
Earnings History > 9 > eps Actual
0.67
Earnings History > 9 > eps Estimate
1.05
Earnings History > 9 > eps Difference
-0.38
Earnings History > 9 > surprise Percent
-36.1905
Earnings History > 10 > period
2023-06-30
Earnings History > 10 > report Date
2023-08-07
Earnings History > 10 > date
2023-06-30
Earnings History > 10 > before After Market
AfterMarket
Earnings History > 10 > currency
EUR
Earnings History > 10 > eps Actual
-0.79
Earnings History > 10 > eps Estimate
-0.8335
Earnings History > 10 > eps Difference
0.0435
Earnings History > 10 > surprise Percent
5.219
Earnings History > 11 > period
2023-03-31
Earnings History > 11 > report Date
2023-05-08
Earnings History > 11 > date
2023-03-31
Earnings History > 11 > before After Market
AfterMarket
Earnings History > 11 > currency
EUR
Earnings History > 11 > eps Actual
2.05
Earnings History > 11 > eps Estimate
0.2651
Earnings History > 11 > eps Difference
1.7849
Earnings History > 11 > surprise Percent
673.2931
Earnings History > 12 > period
2022-12-31
Earnings History > 12 > report Date
2023-03-27
Earnings History > 12 > date
2022-12-31
Earnings History > 12 > before After Market
AfterMarket
Earnings History > 12 > currency
EUR
Earnings History > 12 > eps Actual
9.26
Earnings History > 12 > eps Estimate
7.35
Earnings History > 12 > eps Difference
1.91
Earnings History > 12 > surprise Percent
25.9864
Earnings History > 13 > period
2022-09-30
Earnings History > 13 > report Date
2022-11-07
Earnings History > 13 > date
2022-09-30
Earnings History > 13 > before After Market
AfterMarket
Earnings History > 13 > currency
EUR
Earnings History > 13 > eps Actual
6.98
Earnings History > 13 > eps Estimate
3.42
Earnings History > 13 > eps Difference
3.56
Earnings History > 13 > surprise Percent
104.0936
Earnings History > 14 > period
2022-06-30
Earnings History > 14 > report Date
2022-08-08
Earnings History > 14 > date
2022-06-30
Earnings History > 14 > before After Market
BeforeMarket
Earnings History > 14 > currency
EUR
Earnings History > 14 > eps Actual
6.45
Earnings History > 14 > eps Estimate
7.08
Earnings History > 14 > eps Difference
-0.63
Earnings History > 14 > surprise Percent
-8.8983
Earnings History > 15 > period
2022-03-31
Earnings History > 15 > report Date
2022-05-09
Earnings History > 15 > date
2022-03-31
Earnings History > 15 > before After Market
-
Earnings History > 15 > currency
EUR
Earnings History > 15 > eps Actual
14.24
Earnings History > 15 > eps Estimate
14.24
Earnings History > 15 > eps Difference
0
Earnings History > 15 > surprise Percent
0
Earnings History > 16 > period
2021-12-31
Earnings History > 16 > report Date
2022-03-30
Earnings History > 16 > date
2021-12-31
Earnings History > 16 > before After Market
-
Earnings History > 16 > currency
EUR
Earnings History > 16 > eps Actual
12.18
Earnings History > 16 > eps Estimate
12.18
Earnings History > 16 > eps Difference
0
Earnings History > 16 > surprise Percent
0
Earnings History > 17 > period
2021-09-30
Earnings History > 17 > report Date
2021-11-09
Earnings History > 17 > date
2021-09-30
Earnings History > 17 > before After Market
-
Earnings History > 17 > currency
EUR
Earnings History > 17 > eps Actual
12.35
Earnings History > 17 > eps Estimate
12.35
Earnings History > 17 > eps Difference
0
Earnings History > 17 > surprise Percent
0
Earnings History > 18 > period
2021-06-30
Earnings History > 18 > report Date
2021-08-09
Earnings History > 18 > date
2021-06-30
Earnings History > 18 > before After Market
-
Earnings History > 18 > currency
EUR
Earnings History > 18 > eps Actual
10.77
Earnings History > 18 > eps Estimate
10.77
Earnings History > 18 > eps Difference
0
Earnings History > 18 > surprise Percent
0
Earnings History > 19 > period
2021-03-31
Earnings History > 19 > report Date
2021-05-10
Earnings History > 19 > date
2021-03-31
Earnings History > 19 > before After Market
-
Earnings History > 19 > currency
EUR
Earnings History > 19 > eps Actual
4.39
Earnings History > 19 > eps Estimate
4.39
Earnings History > 19 > eps Difference
0
Earnings History > 19 > surprise Percent
0
Earnings History > 20 > period
2020-12-31
Earnings History > 20 > report Date
2021-03-30
Earnings History > 20 > date
2020-12-31
Earnings History > 20 > before After Market
-
Earnings History > 20 > currency
EUR
Earnings History > 20 > eps Actual
1.15
Earnings History > 20 > eps Estimate
1.45
Earnings History > 20 > eps Difference
-0.3
Earnings History > 20 > surprise Percent
-20.6897
Earnings History > 21 > period
2020-09-30
Earnings History > 21 > report Date
2020-11-10
Earnings History > 21 > date
2020-09-30
Earnings History > 21 > before After Market
-
Earnings History > 21 > currency
EUR
Earnings History > 21 > eps Actual
-0.88
Earnings History > 21 > eps Estimate
-0.88
Earnings History > 21 > eps Difference
0
Earnings History > 21 > surprise Percent
0
Earnings History > 22 > period
2020-06-30
Earnings History > 22 > report Date
2020-08-11
Earnings History > 22 > date
2020-06-30
Earnings History > 22 > before After Market
-
Earnings History > 22 > currency
EUR
Earnings History > 22 > eps Actual
-0.38
Earnings History > 22 > eps Estimate
-0.38
Earnings History > 22 > eps Difference
0
Earnings History > 22 > surprise Percent
0
Earnings History > 23 > period
2020-03-31
Earnings History > 23 > report Date
2020-05-12
Earnings History > 23 > date
2020-03-31
Earnings History > 23 > before After Market
-
Earnings History > 23 > currency
EUR
Earnings History > 23 > eps Actual
-0.24
Earnings History > 23 > eps Estimate
-0.24
Earnings History > 23 > eps Difference
0
Earnings History > 23 > surprise Percent
0
Earnings History > 24 > period
2019-12-31
Earnings History > 24 > report Date
2020-03-31
Earnings History > 24 > date
2019-12-31
Earnings History > 24 > before After Market
-
Earnings History > 24 > currency
EUR
Earnings History > 24 > eps Actual
-0.26
Earnings History > 24 > eps Estimate
-0.24
Earnings History > 24 > eps Difference
-0.02
Earnings History > 24 > surprise Percent
-8.3333
Earnings History > 25 > period
2019-09-30
Earnings History > 25 > report Date
2019-11-14
Earnings History > 25 > date
2019-09-30
Earnings History > 25 > before After Market
-
Earnings History > 25 > currency
EUR
Earnings History > 25 > eps Actual
-0.14
Earnings History > 25 > eps Estimate
-0.14
Earnings History > 25 > eps Difference
0
Earnings History > 25 > surprise Percent
0
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Stock Price
€0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of BioNTech SE
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
-0.06
Date
2025-09-30
EPS Actual
-0.1194
EPS Estimate
0.1
EPS Difference
-0.2194
Surprise Percent
-219.4%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
€ 0
Cost Of Revenue
€ 0
Gross Profit
€ 0
Operating Expenses
€ 0
Operating Income
€ 0
Interest Expense
€ 0
Pretax Income
€ 0
Net Income
€ 0
Income Tax Expense
€ 0
EBITDA
€ 0
Total Other Income Expense Net
€ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
€ 0
Short Term Investments
€ 0
Receivables
€ 0
Inventories
€ 0
Total Current Assets
€ 0
Property Plant Equipment
€ 0
Total Assets
€ 0
Payables
€ 0
Short Term Debt
€ 0
Long Term Debt
€ 0
Total Liabilities
€ 0
Equity
€ 0
(Last Updated 2025-09-30)
Net Income
€ 0
Depreciation
€ 0
Change In Working Capital
€ 0
Cash From Operations
€ 0
Capital Expenditures
€ 0
Cash From Investing
€ 0
Cash From Financing
€ 0
Net Change In Cash
€ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.